ENGLISH | 中文
Pfizer China Supports Management of Patients with Hypertension
  in Shanghai Community Hospitals
Share :  
  • Shanghai    November 29, 2005

  •  
  • SHANGHAI, November 29th— Pfizer announced today the signing of a memorandum of understanding with the Shanghai's Center for Disease Prevention and Control (Shanghai CDC), in which the company will support Shanghai's community health service through its expertise in management of patients with hypertension and CV risk factors. This program, known as DMaP, has been discussed and agreed by Shanghai Municipal Bureau of Health. Mr. Jeffrey B. Kindler, Vice Chairman of Pfizer Inc, participated in the signing ceremony held at CDC's office in Shanghai today.

    Cardiovascular diseases are the leading cause of both death and disease burden in urban areas of China such as Shanghai. According to the National Survey on Nutrition and Health Status of Chinese People in 2002, it estimated about 2 million hypertensive patients in Shanghai. However, the awareness, diagnosis and treatment levels are low, resulting in a hypertension control rate of approximately 9.7% in urban areas. The clinical and economic consequences of poorly controlled hypertension are serious. Patients with hypertension need advice, support and information from health professionals in order to understand the importance of maintaining consistent blood pressure control through changes in lifestyle and adherence to a drug regime in order to prevent complications such as stroke and myocardial infarction.

    To address this challenge, Pfizer China has been working closely with Shanghai CDC on a project to fully utilize the resources and infrastructure of Tier I hospitals as well as the expertise of Tier III to support the diagnosis and management of patients with hypertension in the community to encourage more patients to visit community hospitals for better management of chronic disease.

    DMaP is designed to provide education and training for selected community hospital physicians to improve their theoretical and practical skills, while simultaneously providing patients supportive education and training materials to help them better manage their disease and achieve treatment goals, thereby improving outcomes and cost measures for the government. Moreover, a key component of the program is the development of a technology platform that will provide a user-interface for physicians to identify and monitor the needs of individual patients and design a flexible management program tailored to patient needs comprised of the right balance of education/counseling, intervention and/or specialist referral.

    "Pfizer has significant experience and expertise in developing and implementing successful disease management programs in this area – Pfizer Health Solutions in Florida (US) and Haringey (UK) are recent examples," said Mr. Allan Gabor, the Chairman and General Manager of Pfizer China. "Given Pfizer's interest in aligning with the Shanghai government’s initiative of improving management of chronic disease in the community, we have decided to collaborate closely with the Shanghai CDC in the development and implementation of a pilot CV disease management program known as DMaP. "

    Pfizer is dedicated to discovering and developing innovative medicines and making them available to people around the world. Our business is fundamentally about saving, improving and enhancing lives, and we believe that by being successful as a business we provide the greatest benefit to society. Our commitment to being an exemplary corporate citizen is reflected in our extensive efforts to improve access to healthcare, the core focus of this initiative, and a governing principle in the way we do business. We strive to make every country and community in which we operate a better place to live and work.

    If you have any more questions about this, please contact with
    Pfizer China, Tel: 010 65880288

     


Text SizeAAA